Co-infection with human immunodeficiency virus-1 (HIV) and syphilis is associated with rapid progression to tertiary syphilis. This case report describes the early development of gummatous skin disease and suspected neurosyphilis in a patient with untreated HIV and approaches to treatment.
INTRODUCTION
We present a case of a 25-year-old man with a 5-year history of untreated HIV-1, who was admitted to a mental health unit with acute psychosis and referred to our infectious diseases facility in April 2017 with an incidental finding of two deep ulcerating skin lesions on his mid-back ( Fig. 1) and right forearm. The lesions were tender and had developed over the previous 2 weeks. The patient is of Aboriginal and Torres Strait Islander descent, with a history of bipolar disorder, cannabinoid and amphetamine use and unprotected sex with men. He was diagnosed with HIV in 2012 but declined treatment. He reports being stigmatised at the time of diagnosis and consequently had an intense fear of disclosing his HIV status.
It was later discovered that 2 years previously, a primary penile chancre had been identified, which a polymerase chain reaction test showed was positive for syphilis. He was then partially treated on three occasions by three different general practitioners. In April 2015 he received five sporadic i.m. procaine injections as part of a prescribed 10-day course, then 3 months later a 14-day course of oral doxycycline 100 mg b.i.d. In June 2016 he received another 14-day course of doxycycline 100 mg b.i.d. and a prescription for i.m. benzathine that was never filled. On each occasion he did not take the therapy prescribed and was eventually lost to follow up. He did not disclose his HIV status to any of his general practitioners, and no syphilis serology was done in 2015.
There were no focal neurological, cardiac or ophthalmological abnormalities on examination. His HIV-1 viral load was 122, 762 copies/mL, his CD4 + T lymphocyte count (CD4 count) was 200 cells/lL (19%), his rapid plasma reagin titre was 128 and his Treponema pallidum particle agglutination (TPPA) titre >320. Screening for hepatitis B, C, chlamydia and gonorrhoea were negative.
A biopsy of the skin lesions showed deep ulceration with a necrotic and suppurative base. The mid-dermis and deep dermis showed a prominent peri-adnexal and perivascular inflammatory infiltrate including numerous plasma cells. A focus of folliculitis was associated with a poorly formed non-caseating granuloma, most suggestive of follicle rupture. Spirochetes were difficult to identify on a WarthinStarry stain due to marked background staining. Numerous spirochetes were identified on a spirochete (T. pallidum) immunohistochemical stain at the dermo-epidermal junction and throughout the upper and mid dermis (Fig. 2) .
Magnetic resonance imaging of the brain revealed no meningeal enhancement or other intracranial pathology, but right-sided mastoiditis was evident and may have represented a bony gumma. The cerebrospinal fluid was acellular, protein 0.26 g/dL and glucose 3.0 mmol/L, with the cerebrospinal fluid HIV-1 viral load 14 780 copies/mL. The cerebrospinal fluid syphilis studies were discordant, with a negative venereal disease research laboratory test but a positive fluorescent treponemal antibody test. The cerebrospinal fluid TPPA titre was 160, and the cerebrospinal fluid treponemal polymerase chain reaction was negative. Blood contamination of the cerebrospinal fluid was excluded through a negative screen for adenovirus immunoglobulin G in the sample.
The patient responded to olanzapine and commenced combination antiretroviral therapy with dolutegravir, abacavir and lamivudine following negative testing for HLA-B5701. I.v. benzylpencillin 2.4-g 6-hourly was commenced for tertiary gummatous syphilis and possible neurosyphilis. Within 5 days his skin lesions had improved. The patient had received 10 days of i.v. benzylpenicillin before he absconded from the ward and was lost to follow up. After 8 months he re-presented briefly to the HIV service, at which point a complete resolution of the skin lesions was observed and the rapid plasma reagin titre had reduced from 128 to 8. Follow up magnetic resonance imaging could not be performed before the patient defaulted from follow up again.
DISCUSSION
The natural history of untreated syphilis has been well documented in the era before antibiotics. In men who have sex with men with primary and secondary syphilis, the rates of HIV co-infection have been reported to be as high as 50% in Sydney and the USA, compared with 10% in men who have intercourse with women. 1 In this population two other major risk factors are amphetamine use and multiple sexual partners. The gumma is a granulomatous necrotising inflammatory response to a small number of spirochetes. Gummatous lesions are a manifestation of tertiary syphilis and may form within any organ, most commonly in the skeleton and skin. Gummas usually occur between 4 and 10 years after infection; however, in patients with HIV they may arise within a few months. 2 Cutaneous manifestations of syphilis may be present in primary, secondary and tertiary disease, and the overlap of features between stages is well recognised. 3 Histopathologically, gummas typically have plasmacytic infiltration and positive Warthin-Starry staining for spirochetes, similar to chancres, but additionally are characterised by granuloma formation. 4 The spirochete immunohistochemical stain is more sensitive and specific than the Warthin-Starry stain. 5 Lue maligna (also known as ulceronodular syphilis) is another rare dermatological manifestation of secondary syphilis usually seen in patients with HIV and it also has granuloma formation seen on histopathology, but it has fewer or absent spirochetes compared with gummas. 6 Lue maligna is typically associated with a prodrome of fever, chills and malaise. Gummas are infrequently reported in the post-antibiotic era and may be underrecognised, given that the characteristic biopsy findings may overlap with other syphilitic and non-syphilitic inflammatory lesions. Spirochetes may also be difficult to identify on Warthin-Starry stain, and a T. pallidum immunohistochemical stain may not be readily available or contemplated. Patients' characteristics, including untreated HIV, a low CD4 count and positive syphilis serology with high rapid plasma reagin titres are consistent with tertiary gummatous disease and should prompt consideration of this diagnosis. Patients with HIV tend to progress rapidly from early syphilis to neurosyphilis, and are more likely to do so with a CD4 count <350 cells/lL and a rapid plasma reagin titre >1:128.
7 Furthermore syphilis co-infection is associated with a transient increase in HIV viral load and a decreased CD4 count, and the rapid progression of HIV, even in patients on antiretroviral therapy. 8 Thus, in a patient with HIV and syphilis, a cerebrospinal fluid analysis should be conducted if there are any neurological signs or if there is ocular involvement. It should be strongly considered with a CD4 count <350 cells/lL, a venereal disease research laboratory/reactive plasma reagin titre of >1:32, and when the patient is antiretroviral therapy naive. Interpretation of cerebrospinal fluid serology centres on the sensitivity and specificity of fluorescent treponemal antibody and venereal disease research laboratory test for neurosyphilis. A reactive cerebrospinal fluid venereal disease research laboratory test, without blood contamination, is considered to be diagnostic of neurosyphilis. Although this is a very specific test, it lacks sensitivity, and a negative test result does not exclude neurosyphilis. Reports of its diagnostic sensitivity range from 50 to 72%. 10 In contrast, the cerebrospinal fluid fluorescent treponemal antibody test is sensitive but less specific, especially in cases with an acellular cerebrospinal fluid. A cerebrospinal fluid polymerase chain reaction test is not usually considered to be useful in the diagnosis of neurosyphilis, in light of its poor sensitivity and specificity. Moderate cerebrospinal fluid pleocytosis is characteristic of both HIV and neurosyphilis and therefore relatively unhelpful in diagnosing HIV co-infection.
Treatment guidelines vary internationally due to the paucity of evidence. Australian therapeutic guidelines recommend 15 days of i.v. benzylpenicllin 1.8 g 4-hourly for the treatment of tertiary syphilis and neurosyphilis. However the Infectious Diseases Society of America, the Centers for Disease Control and British Association for Sexual Health and HIV 11 all recommend weekly i.m. benzathine for 3 weeks for treating gummatous and cardiovascular syphilis, and reserve i.v. therapy for neurosyphilis alone.
High rates of primary syphilis have become a public health concern among HIV-positive men who have sex with men in inner Sydney, with a 12-fold increase in syphilis notifications in the last decade, and re-infection rates doubling from 9 to 19%. 1, 12 Our patient highlights the challenges in syphilis and HIV surveillance, management and follow up in the community, particularly in the context of additional mental health comorbidity, drug use and stigma.
CONCLUSION
Rapid progression to tertiary syphilis is more likely in the context of HIV-associated immunodeficiency. Our patient highlights the rare and possibly underrecognised dermatological manifestations of gummatous disease in patients with HIV and the complexities of syphilis management from both a patient and a public health perspective when confounded by mental health issues. Inconsistencies between international guidelines for the treatment of tertiary syphilis and the diagnosis of neurosyphilis present a diagnostic and therapeutic challenge.
